Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer.
Marshall DC, Lyman SK, McCauley S, Kovalenko M, Spangler R, Liu C, Lee M, O'Sullivan C, Barry-Hamilton V, Ghermazien H, Mikels-Vigdal A, Garcia CA, Jorgensen B, Velayo AC, Wang R, Adamkewicz JI, Smith V. Marshall DC, et al. Among authors: mccauley s. PLoS One. 2015 May 11;10(5):e0127063. doi: 10.1371/journal.pone.0127063. eCollection 2015. PLoS One. 2015. PMID: 25961845 Free PMC article.
Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.
Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, Garcia CA, Velayo AC, Jorgensen B, Biermann D, Tsai D, Green J, Zaffryar-Eilot S, Holzer A, Ogg S, Thai D, Neufeld G, Van Vlasselaer P, Smith V. Barry-Hamilton V, et al. Among authors: mccauley s. Nat Med. 2010 Sep;16(9):1009-17. doi: 10.1038/nm.2208. Epub 2010 Sep 5. Nat Med. 2010. PMID: 20818376
PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia.
Chan IH, Van Hoof D, Abramova M, Bilardello M, Mar E, Jorgensen B, McCauley S, Bal H, Oft M, Van Vlasselaer P, Mumm JB. Chan IH, et al. Among authors: mccauley s. PLoS One. 2016 Jun 14;11(6):e0156229. doi: 10.1371/journal.pone.0156229. eCollection 2016. PLoS One. 2016. PMID: 27299860 Free PMC article.
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. Naing A, et al. Among authors: mccauley s. Lancet Oncol. 2019 Nov;20(11):1544-1555. doi: 10.1016/S1470-2045(19)30514-5. Epub 2019 Sep 25. Lancet Oncol. 2019. PMID: 31563517 Free PMC article. Clinical Trial.
IL-10: Expanding the Immune Oncology Horizon.
Chan IH, Wu V, McCauley S, Grimm EA, Mumm JB. Chan IH, et al. Among authors: mccauley s. Receptors Clin Investig. 2015;2(4):1041. Epub 2015 Nov 4. Receptors Clin Investig. 2015. PMID: 26661378 Free PMC article.
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.
Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. Naing A, et al. Among authors: mccauley s. Cancer Cell. 2018 Nov 12;34(5):775-791.e3. doi: 10.1016/j.ccell.2018.10.007. Cancer Cell. 2018. PMID: 30423297 Free PMC article.
243 results